Latest news with #CarterGould
Irish Examiner
31-07-2025
- Business
- Irish Examiner
Botox maker AbbVie raises profit forecast after strong sales of immunology drugs
AbbVie, the makers of Botox, raised its 2025 profit forecast on Thursday, after beating Wall Street estimates for second-quarter results on strong sales of its newer immunology drugs Skyrizi and Rinvoq. AbbVie's forecast raise comes on the back of the European Union's framework trade deal with the United States, under which all EU-produced pharmaceuticals entering the US will be subject to a 15% tariff. AbbVie has a significant presence in Ireland, in Dublin, Sligo, in Carrigtwohill in Co Cork, and in Westport in Mayo, where it makes its wrinkle treatment Botox. Shares of the drugmaker jumped nearly 6%. The company is pushing Skyrizi and Rinvoq to counter the drop in sales of arthritis treatment Humira, as the once-bestselling drug faces competition from several cheaper biosimilars that began hitting the US market in 2023. "We're entering the second half of the year with substantial momentum," said CEO Robert Michael. Skyrizi recorded quarterly sales of $4.42bn (€3.86bn), beating analysts' average estimate of $4bn, while Rinvoq sales of $2.03bn surpassed estimates of $1.97 billion, according to data compiled by LSEG. The Chicago drugmaker has spent more than $20bn (€17.4bn) on acquisitions since 2023 as Humira lost patent protection. On Wednesday, Bloomberg News reported that AbbVie is in talks to acquire privately held psychiatric disorder drug developer Gilgamesh Pharmaceuticals in a deal worth about $1bn (€870m). Global sales of Humira, once the world's best-selling drug, came in at $1.18bn (€1.03bn) in the second quarter, missing estimates of $1.45bn (€1.27bn). The company now expects adjusted annual profit per share between $11.88 and $12.08, compared with its previous expectations of $11.67 to $11.87. Cantor Fitzgerald analyst Carter Gould said AbbVie "delivered the stand-out print so far across large-cap biopharma." The company earned quarterly adjusted profit per share of $2.97, compared with estimates of $2.88. Established in 1977, AbbVie's Westport facility employs approximately 1,300 people. The campus has grown to almost 750,000 sq. ft. on a 61-acre campus, and it encompasses a pharmaceuticals facility, two biologics plants and an ocular implant facility that manufactures a range of leading eye care products. The company's plant in Carrigtwohill is a modern 'bulk tablet' facility manufacturing solid and capsule formulations. Reuters
Yahoo
03-07-2025
- Business
- Yahoo
Cantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP Meeting
Vaxcyte Inc. (NASDAQ:PCVX) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 10, Cantor Fitzgerald reiterated its Overweight rating for Vaxcyte Inc. (NASDAQ:PCVX). The update comes amid speculation regarding the potential effects on pneumococcal vaccine developers following the upcoming meeting of the Advisory Committee on Immunization Practices (ACIP). Cantor Fitzgerald analyst Carter Gould explained the firm's position on Vaxcyte Inc. (NASDAQ:PCVX), pointing out that the upcoming ACIP meeting is unlikely to focus much on pneumococcal disease. This implies that the meeting's talks will have a direct impact on Vaxcyte's operations or prospects. Gould also noted that the potential approval and ACIP recommendation of Vaxcyte's vaccination efforts are still a few years away. The analyst also highlighted the strength of the pneumococcal conjugate vaccine (PCV) data from Vaxcyte Inc. (NASDAQ:PCVX). Gould said that the robustness of this evidence makes a compelling case for sticking with tried-and-true vaccination practices. A clinical-stage vaccine pioneer, Vaxcyte, Inc. (NASDAQ:PCVX) develops, refines, and produces high-fidelity vaccines. The company's medications aim to prevent or cure bacterial illnesses such as Shigella, Group A Strep, invasive pneumococcal disease, and periodontitis. While we acknowledge the potential of PCVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Globe and Mail
25-06-2025
- Business
- Globe and Mail
Cantor Fitzgerald Sticks to Their Hold Rating for Amgen (AMGN)
In a report released today, Carter Gould from Cantor Fitzgerald maintained a Hold rating on Amgen (AMGN – Research Report), with a price target of $305.00. The company's shares closed yesterday at $272.44. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Gould covers the Healthcare sector, focusing on stocks such as Amgen, Eli Lilly & Co, and Pfizer. According to TipRanks, Gould has an average return of 3.4% and a 46.44% success rate on recommended stocks. Amgen has an analyst consensus of Moderate Buy, with a price target consensus of $325.56, which is a 19.50% upside from current levels. In a report released today, Citi also maintained a Hold rating on the stock with a $300.00 price target. AMGN market cap is currently $155.6B and has a P/E ratio of 26.41.
